High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples